Quotient Bioresearch and KWS BioTest become partners
PRESS RELEASE: Quotient Bioresearch and KWS BioTest partner to deliver end-to-end anti-infectives screening.
Cambridge, UK & Bristol, UK, 9 May 2011 – Two leading contract research organisations,Quotient Bioresearch Ltd. and KWS BioTest Ltd.,
have today announced a new strategic partnership to provide a novel co-ordinated approach to support the development of new antimicrobial agents.
The partnership – unveiled at the 21st European Congress of Clinical Microbiology and Infectious Diseases 2011 (ECCMID 2011) in Milan, Italy – will enable the two companies to provide high quality screening of anti-infectives all the way from in vitro activity assays , efficacy and resistance profiling through validated models of human disease to clinical investigations, with full scientific support.
Dr. Ian Morrissey, Director of Anti-Infectives at Quotient, explained: “With KWS we can now provide a unique and fully-integrated ‘Plate to Patient’ offering for our anti-infective clients, including anti-virals and models of human disease.
The new partnership has been created following a longstanding relationship between Quotient and KWS and represents significant expansion in the industry for both companies. Sharing a number of joint customers, the synergy created through this collaboration will enable both companies to carry out larger integrated studies for their clients.
Prof. Neil Williams, Director of Science at KWS BioTest, is excited to formalise an agreement with Quotient. He commented: “Both companies have established themselves on a basis of providing a high quality of service, scientific understanding and support to their clients.”
Ian Morrissey and Leann Quinn (Business Development Manager at KWS) will be available for discussions at the 21st ECCMID conference, where Ian will also be holding a presentation at 16:00 on Monday, May 9 on Activity of ceftaroline against serotyped Streptococcus pneumoniae isolates from Europe (2007-2008). In addition, Quotient Bioanalytical Sciences is showcasing its latest suite of posters at its booth, number 629.
For further information about Quotient Bioresearch Ltd. visit the website at www.quotientbioresearch.com/bioanalytical-sciences. Further information about KWS BioTest Ltd. can be found at www.kwsbiotest.co.uk/
About Quotient Bioresearch Ltd.
Quotient Bioresearch is a leading provider of early-stage and specialist drug development services to pharmaceutical, biotechnology, and medical-device clients worldwide. The company offers a wide range of drug development services through its three key focus areas: Chemistry and Metabolism, Bioanalytical Sciences, including Microbiology, and Clinical. Quotient has grown rapidly in the past 3 years, through a combination of acquisition-led and organic growth. An early acquisition for Quotient was London-based GR Micro Ltd., bringing to the group more than 25 years’ experience in antimicrobial discovery and development, and now availed of state-of-the-art, purpose-built laboratories within our Cambridgeshire site. Internationally recognised as leaders in providing true expertise in analytical services for antimicrobial development, we are dedicated to supporting projects of all sizes, from early discovery through to late-phase clinical trials and global resistance surveillance studies.
About KWS BioTest Ltd.
KWS BioTest Ltd was established in 2004 as a CRO, bringing together internationally renowned scientific expertise in a commercially managed environment. KWS offers a wide range of preclinical services from primary and secondary screens through to complex disease models in the areas of infection, inflammation, autoimmunity, allergy, pain and metabolic disease. In all of these areas, KWS combines analysis of traditional disease parameters with bioanalytical and pathology services in order to work with our customers to design and deliver bespoke programmes that meet with their expectations.